Evidence map›Paper›PMID 22135472›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2011

Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Cassandra B Jabara, Corbin D Jones, Jeffrey Roach, Jeffrey A Anderson, Ronald Swanstrom

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 254 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 2 syntheses or guidelines pooled it, 384 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Portable Nanopore sequencing solution for next-generation HIV drug resistance testing.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2024
    Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Full-spectrum HIV drug resistance mutation detection by high-resolution complete pol gene sequencing.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2023
    Article

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Cassandra B JabaraDepartment of Biology, Lineberger Comprehensive Cancer Center, University of North Carolina Center for AIDS Research, Carolina Center for Genome Sciences, Chapel Hill, NC 27599, USA.
Corbin D Jones
Jeffrey Roach
Jeffrey A Anderson
Ronald Swanstrom
Institute of Mathematical Problems of Biology · RUOffice of Infectious Diseases · USSegeberger Kliniken · DEUNC Lineberger Comprehensive Cancer Center

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Targeting ensembles of Drug Resistant HIV ProteasesP01GM066524 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RANA, TARIQ M · 2002 to 2011
$16.3M
Biological properties of HIV-1 V3 evolutionary variantsR37AI044667 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2005 to 2014
$3.4M
NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA16086NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI50410NIAID NIH HHS R37 AI044667NIAID NIH HHS R37 AI44667NIGMS NIH HHS P01 GM066524
6 · The paper itself

Abstract

Viruses can create complex genetic populations within a host, and deep sequencing technologies allow extensive sampling of these populations. Limitations of these technologies, however, potentially bias this sampling, particularly when a PCR step precedes the sequencing protocol. Typically, an unknown number of templates are used in initiating the PCR amplification, and this can lead to unrecognized sequence resampling creating apparent homogeneity; also, PCR-mediated recombination can disrupt linkage, and differential amplification can skew allele frequency. Finally, misincorporation of nucleotides during PCR and errors during the sequencing protocol can inflate diversity. We have solved these problems by including a random sequence tag in the initial primer such that each template receives a unique Primer ID. After sequencing, repeated identification of a Primer ID reveals sequence resampling. These resampled sequences are then used to create an accurate consensus sequence for each template, correcting for recombination, allelic skewing, and misincorporation/sequencing errors. The resulting population of consensus sequences directly represents the initial sampled templates. We applied this approach to the HIV-1 protease (pro) gene to view the distribution of sequence variation of a complex viral population within a host. We identified major and minor polymorphisms at coding and noncoding positions. In addition, we observed dynamic genetic changes within the population during intermittent drug exposure, including the emergence of multiple resistant alleles. These results provide an unprecedented view of a complex viral population in the absence of PCR resampling.

Indexed as

AllelesBase SequenceCodonDNA, ComplementaryDNA PrimersDrug Resistance, Multiple, ViralGenes, ViralGenetic VariationHigh-Throughput Nucleotide SequencingHIV-1HIV ProteaseHumansLinkage DisequilibriumMolecular Sequence DataPhylogenyProtease InhibitorsCodonDNA, ComplementaryDNA PrimersHIV Proteasep16 protease, Human immunodeficiency virus 1Protease InhibitorsRNA, Viral

Identifiers

PMID22135472
PMCPMC3250168
OpenAlexW2163576465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.